Stifel Nicolaus Reaffirms Buy Rating for Nyxoah (NASDAQ:NYXH)

Stifel Nicolaus restated their buy rating on shares of Nyxoah (NASDAQ:NYXH) in a report published on Wednesday morning, Benzinga reports. The firm currently has a $27.00 target price on the stock.

Several other analysts also recently weighed in on the company. HC Wainwright restated a buy rating and issued a $22.00 price objective (up from $18.00) on shares of Nyxoah in a report on Wednesday, March 20th. Oppenheimer increased their target price on shares of Nyxoah from $17.00 to $20.00 and gave the company an outperform rating in a research report on Thursday, March 14th. Piper Sandler boosted their target price on Nyxoah from $15.00 to $20.00 and gave the stock an overweight rating in a research note on Wednesday, March 6th. Finally, Cantor Fitzgerald increased their price target on Nyxoah from $10.00 to $14.00 and gave the company an overweight rating in a research note on Friday, February 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $20.20.

Nyxoah Price Performance

Shares of NYXH stock opened at $10.12 on Wednesday. The company’s 50-day simple moving average is $11.96 and its two-hundred day simple moving average is $9.07. Nyxoah has a one year low of $4.00 and a one year high of $20.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.50 and a current ratio of 3.94.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). The company had revenue of $1.96 million for the quarter, compared to analysts’ expectations of $2.01 million. Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.48%. On average, sell-side analysts anticipate that Nyxoah will post -1.71 EPS for the current year.

Institutional Trading of Nyxoah

An institutional investor recently bought a new position in Nyxoah stock. Ikarian Capital LLC acquired a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 50,699 shares of the company’s stock, valued at approximately $684,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.